(Q34343995)

1 August 2017

title

Phase II trial of sagopilone, a novel epothilone analog in metastatic melanoma (English)

1 reference

ORCID Public Data File 2021

1 August 2017

main subject

phase II clinical trial

0 references

1 reference

1 reference

author name string

R C DeConti

1

1 reference

1 August 2017

A P Algazi

2

1 reference

1 August 2017

S Andrews

3

1 reference

1 August 2017

P Urbas

4

1 reference

1 August 2017

O Born

5

1 reference

1 August 2017

D Stoeckigt

6

1 reference

1 August 2017

L Floren

7

1 reference

1 August 2017

J Hwang

8

1 reference

1 August 2017

J Weber

9

1 reference

1 August 2017

V K Sondak

10

1 reference

1 August 2017

A I Daud

11

1 reference

1 August 2017

language of work or name

English

0 references

publication date

5 October 2010

1 reference

British Journal of Cancer

1 August 2017

published in

1 reference

1 August 2017

volume

103

1 reference

1 August 2017

issue

10

1 reference

1 August 2017

page(s)

1548-1553

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.bjc.6605931

1 August 2017

exact match

0 references

cites work

Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2990578

Phase II trial of weekly patupilone in patients with castration-resistant prostate cancer

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2990578

Sagopilone crosses the blood-brain barrier in vivo to inhibit brain tumor growth and metastases

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2990578

6 July 2018

Cancer statistics, 2008

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2990578

Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2990578

Mechanisms of multidrug resistance: the potential role of microtubule-stabilizing agents

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2990578

Pharmacological effects of formulation vehicles : implications for cancer chemotherapy

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2990578

High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2990578

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2990578

High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2990578

Prognostic factors in 1,521 melanoma patients with distant metastases.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2990578

A randomized phase II study of ixabepilone (BMS-247550) given daily x 5 days every 3 weeks or weekly in patients with metastatic or recurrent squamous cell cancer of the head and neck: an Eastern Cooperative Oncology Group study

6 July 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605931

Paclitaxel disposition in plasma and central nervous systems of humans and rats with brain tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605931

Improved cellular pharmacokinetics and pharmacodynamics underlie the wide anticancer activity of sagopilone

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605931

Total synthesis and antitumor activity of ZK-EPO: the first fully synthetic epothilone in clinical development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605931

Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605931

Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients : randomized phase 2 study of ixabepilone or mitoxantrone and prednisone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605931

Randomized trial of two or five computed tomography scans in the surveillance of patients with stage I nonseminomatous germ cell tumors of the testis: Medical Research Council Trial TE08, ISRCTN56475197--the National Cancer Research Institute Testis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605931

Phase I study of the novel, fully synthetic epothilone sagopilone (ZK-EPO) in patients with solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605931

Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605931

Docetaxel (Taxotere) in advanced malignant melanoma: a phase II study of the EORTC Early Clinical Trials Group

21 January 2018

1 reference

12 December 2020

Phase II trial of docetaxel in patients with advanced cutaneous malignant melanoma previously untreated with chemotherapy

1 reference

12 December 2020

Phase II clinical trial of the epothilone B analog, ixabepilone, in patients with non small-cell lung cancer whose tumors have failed first-line platinum-based chemotherapy

1 reference

12 December 2020

Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine

1 reference

12 December 2020

A phase II study of taxol in patients with malignant melanoma

1 reference

12 December 2020

Identifiers

DOI

10.1038/SJ.BJC.6605931

1 reference

Dimensions Publication ID

1 August 2017

0 references

1 reference

1 August 2017

1 reference